Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...

Merck KGaA, Darmstadt, Germany, a science and technology company, has entered into a definitive agreement to acquire ...

Online retailer Temu — owned by PDD Holdings (PDD) — aims to raise prices amid tariffs, while Tesla (TSLA) raises its EV ...

Two months after confirming “advanced talks” for a potential merger, Stamford-based SpringWorks Therapeutics Inc. on Monday ...

The acquisition provides Merck with immediate access to SpringWorks' approved rare cancer therapies - Ogsiveo for aggressive soft tissue tumors and the recently approved Gomekli for nerve sheath ...

After reported discussions since February, German pharma and sciences company Merck KGaA (MRK: DE) has confirmed its ...

Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add ...

This comprehensive summary outlines Australia's Labor government's plan to enhance healthcare with telehealth services, Merck ...

Merck KGaA said Monday it has inked a “definitive agreement” to acquire Pfizer spinout SpringWorks Therapeutics for an equity value of around $3.9 billion, rounding off several months of negotiations.

U.S. stock futures are little changed as investors ready for a busy earrings calendar, including upcoming reports from Apple, ...

Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business.

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around ...